Drug Trial Radar · NCT00297115
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)
Last checked: Nov 19, 2026Latest source record: Nov 7, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,568
Actual
Start
Mar 2006
Primary completion
Apr 2008
Study completion Aug 2008
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 28, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to compare the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Roflumilast will be administered orally once daily in the morning at one dose level. The study duration will be up to 56 weeks. The study will provide further data on safety and tolerability of roflumilast. For additional information (for US patients only) see www.COPDSTUDY.net or dial 866-788-2673 (toll free).
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
RoflumilastDrug
500 mcg, once daily, oral administration in the morning
PlaceboDrug
once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)Time frame: Change from baseline over 52 weeks of treatment
- COPD Exacerbation Rate (Moderate or Severe)Time frame: 52 weeks treatment period
Locations
287 sites in 8 countries. Site status is shown where the registry gives one.
Altana Pharma/Nycomed Investigational Site
Bayou La Batre, Alabama
Altana Pharma/Nycomed Investigational Site
Birmingham, Alabama
Altana Pharma/Nycomed Investigational Site
Birmingham, Alabama
Altana Pharma/Nycomed Investigational Site
Huntsville, Alabama
Altana Pharma/Nycomed Investigational Site
Bullhead City, Arizona
Altana Pharma/Nycomed Investigational Site
Phoenix, Arizona
Altana Pharma/Nycomed Investigational Site
Phoenix, Arizona
Altana Pharma/Nycomed Investigational Site
Fort Smith, Arkansas
Altana Pharma/Nycomed Investigational Site
Little Rock, Arkansas
Altana Pharma/Nycomed Investigational Site
Anaheim, California
Altana Pharma/Nycomed Investigational Site
Burbank, California
Altana Pharma/Nycomed Investigational Site
Carlsbad, California
Altana Pharma/Nycomed Investigational Site
Fresno, California
Altana Pharma/Nycomed Investigational Site
Lakewood, California
Altana Pharma/Nycomed Investigational Site
Long Beach, California
Altana Pharma/Nycomed Investigational Site
Los Alamitos, California
Altana Pharma/Nycomed Investigational Site
Los Angeles, California
Altana Pharma/Nycomed Investigational Site
Roseville, California
Altana Pharma/Nycomed Investigational Site
Sacramento, California
Altana Pharma/Nycomed Investigational Site
San Diego, California
Altana Pharma/Nycomed Investigational Site
San Diego, California
Altana Pharma/Nycomed Investigational Site
Sepulveda, California
Altana Pharma/Nycomed Investigational Site
Stockton, California
Altana Pharma/Nycomed Investigational Site
Denver, Colorado
Altana Pharma/Nycomed Investigational Site
Waterbury, Connecticut
Altana Pharma/Nycomed Investigational Site
Washington D.C., District of Columbia
Altana Pharma/Nycomed Investigational Site
Clearwater, Florida
Altana Pharma/Nycomed Investigational Site
DeLand, Florida
Altana Pharma/Nycomed Investigational Site
Fort Lauderdale, Florida
Altana Pharma/Nycomed Investigational Site
Jacksonville, Florida
Altana Pharma/Nycomed Investigational Site
Miami, Florida
Altana Pharma/Nycomed Investigational Site
Miami, Florida
Altana Pharma/Nycomed Investigational Site
Miami Beach, Florida
Altana Pharma/Nycomed Investigational Site
Ocala, Florida
Altana Pharma/Nycomed Investigational Site
Ormand Beach, Florida
Altana Pharma/Nycomed Investigational Site
Port Orange, Florida
Altana Pharma/Nycomed Investigational Site
Tamarac, Florida
Altana Pharma/Nycomed Investigational Site
Vero Beach, Florida
Altana Pharma/Nycomed Investigational Site
Atlanta, Georgia
Altana Pharma/Nycomed Investigational Site
Blue Ridge, Georgia
Showing 40 of 287 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.